Five financial analysts have provided varied opinions on Roivant Sciences (NASDAQ:ROIV) over the past three months, with recent ratings showing 3 bullish, 1 somewhat bullish, and 1 indifferent. The average 12-month price target is $14.8, with a high of $17.00 and a low of $12.00, slightly up from the previous $14.67 average. Analysts from B of A Securities, Deutsche Bank, Guggenheim, and JP Morgan have adjusted their ratings and price targets, reflecting their latest views on the company's performance. Roivant Sciences, a biopharmaceutical company, has shown a significant revenue growth rate of 196.03% as of September 30, 2023, but struggles with profitability and efficiency, as indicated by its net margin of -820.27%, ROE of -32.74%, and ROA of -14.48%.